REG - ValiRx PLC - Operational Update

ValiRxAnnouncement

31/01/2023 07:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230131:nRSe3257Oa&default-theme=true

RNS Number : 3257O  ValiRx PLC  31 January 2023

ValiRx PLC

("ValiRx" or the "Company")

Operational Update

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on
early-stage cancer therapeutics and women's health, is pleased to announce
today the signature of a lease for laboratory space at MediCity (Nottingham).
We are also pleased to confirm the permanent appointment of Dr Cathy
Tralau-Stewart as Chief Scientific Officer ("CSO").

Laboratory Lease

MediCity (Nottingham) is part of Pioneer Group,
https://thepioneergroup.com/locations/medicity-nottingham/
(https://eu-west-1.protection.sophos.com?d=thepioneergroup.com&u=aHR0cHM6Ly90aGVwaW9uZWVyZ3JvdXAuY29tL2xvY2F0aW9ucy9tZWRpY2l0eS1ub3R0aW5naGFtLw==&i=NTdmYjZhY2YwMGFiZGYxNGYzOTNjYzlm&t=dmNSSnVIR21NTWpGZitMaENiNVE2YzhpY3kvK0tzWVpCV09QZUdyRmRhZz0=&h=068db76c5e3d43f0b095dcab38b8f731&s=AVNPUEhUT0NFTkNSWVBUSVZzrLLcin7dTIMjshkwZauRXlmFkrRMLJ37EalYXFOwyQ)
. Conveniently located in the East Midlands, MediCity has access to the local
and national biotech community, access to quality talent from nearby
universities and flexible laboratory space.  The facilities confirmed under
this lease agreement consist of a 910 square foot laboratory space, suitable
for 6-8 lab-based staff members.  Services provided include laboratory
support, access to shared equipment and social events.

This completes the first stage of the establishment of ValiRx's internal
translational Contract Research Organisation ("tCRO") and forms the basis of
the overall tCRO strategy. Work now continues on building a first-class
science and operational team and the implementation of testing techniques that
will help to improve biological understanding of ValiRx's collaborative
development pipeline and, in due course, third party services.

Chief Scientific Officer

Dr Cathy Tralau-Stewart was appointed as Interim CSO for ValiRx in 2022 under
a consultancy arrangement.   We are delighted to announce that Cathy has
agreed to become CSO on a permanent basis, focusing on developing a
risk-balanced, collaborative preclinical pipeline. She will also actively
support the Company strategically through membership of the Executive team and
as a Board observer.

ValiRx CEO, Dr Suzy Dilly commented: "Working with Cathy in the capacity as
Interim CSO over the past few months has demonstrated the value of the role
and that her expertise is an excellent fit for the challenges that ValiRx
faces, so I am delighted to be able to confirm that she's agreed to convert to
a permanent role.  Her knowledge of early-stage drug development and
extensive contacts in the industry will enhance our ability to identify and
translate science into effective treatments.

"Additionally, confirming the signing of the laboratory lease enables us to
build the lab team, accelerate development of our internal programmes at
reduced cost and initiates the launch of the external tCRO service offering."

ValiRx CSO, Dr Cathy Tralau-Stewart added: "ValiRx is progressing an
innovative portfolio of projects to address the important areas of oncology
and the unmet need in the women's health space. I have enjoyed working with
the ValiRx team and am excited to accept a permanent role and to be part of
building its future. The development of the tCRO is an important step forward
and will fill the need for robust and reliable validated translational models
in these areas."

 

 

 

The Directors of the Company take responsibility for this announcement.

 

For more information, please contact:

 

 ValiRx plc                                          Tel: +44 (0) 2476 796496

                                                     www.valirx.com (http://www.valirx.com)

 Dr Suzanne Dilly, CEO                               Suzanne.Dilly@valirx.com (mailto:Suzanne.Dilly@valirx.com)

 V Formation (Public Relations)                      +44 (0) 115 787 0206

                                                     www.vformation.biz (http://www.vformation.biz)

 Lucy Wharton - Senior PR Executive

 Sue Carr - Director                                 lucy@vformation.biz

                                                     sue@vformation.biz
 Cairn Financial Advisers LLP (Nominated Adviser)    Tel: +44 (0) 20 7213 0880

 Liam Murray/Jo Turner/Ludovico Lazzaretti

 Cenkos Securities plc (Joint Broker)                Tel: +44 (0) 20 7397 8900

 Russell Kerr/Michael Johnson (Sales)

 Callum Davidson/Giles Balleny (Corporate Finance)
 Turner Pope Investments (Joint Broker)              Tel: +44 (0) 20 3657 0050

 James Pope / Andy Thacker

 

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics
and women's health, accelerating the translation of innovative science into
impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for
enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development,
the team at ValiRx selects and incubates promising novel drug candidates and
guides them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and
commercial domains, with the aim of achieving a more streamlined, less costly,
drug development process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for science to
advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006
and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com (http://www.valirx.com)

 

Cautionary statement

Certain statements made in this announcement are forward-looking statements.
Such statements are based on current expectations and assumptions and are
subject to a number of risks and uncertainties that could cause actual events
or results to differ materially from any expected future events or results
expressed or implied in these forward-looking statements. Persons receiving
this announcement should not place undue reliance on forward-looking
statements. Unless otherwise required by applicable law, regulation or
accounting standard, the Company does not undertake to update or revise any
forward-looking statements, whether as a result of new information, future
developments or otherwise.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDWPUCPGUPWPUU